Evaluating the Effectiveness of the Nurse Ned Clinic

Titre officiel

Virtualizing Survivorship: Implementing a More Timely and Comprehensive Model of Follow-up Care: Effectiveness Evaluation Phase

Sommaire:

L’objectif de cet essai contrôlé sans répartition aléatoire est d’évaluer l’efficacité d’une clinique virtuelle de survie dirigée par des infirmiers destinée aux patients ayant survécu à un cancer de la prostate (CP). Dans le cadre de cet essai, les chercheurs compareront les résultats prédéterminés en matière de survie de patients de sexe masculin bénéficiant du modèle traditionnel de soins virtuels pour le cancer de la prostate dirigé par des spécialistes (Specialist Ned) à ceux de patients bénéficiant du nouveau modèle de soins virtuels du cancer de la prostate dirigé par des infirmiers (Nurse Ned). Au total, d’après les prévisions, un maximum de 600 hommes (300 dans le groupe témoin; 300 dans le groupe d’intervention) répartis dans cinq centres cliniques (3 en Ontario; 1 en Alberta; et 1 en Nouvelle-Écosse) seront inscrits à cet essai et seront suivis pendant 12 mois.

Description de l'essai

Primary Outcome:

  • Changes in unmet needs
Secondary Outcome:
  • Changes to Participant's Health Status
  • Changes in Prostate Cancer health related quality of life
  • Changes in overall health related quality of life
  • Changes in Psychological Wellbeing
  • Changes in willingness to self-manage
  • Changes to satisfaction with care
  • Changes in health behaviours

Prostate cancer (PCa) is the most common cancer among Canadian men, with over 25,000 diagnosed yearly. While advances in treatment and care, including the PSA (prostate-specific antigen) test have resulted in more men entering survivorship and living longer, many continue to experience undesirable symptoms, side effects and psychosocial concerns. The current healthcare system is not optimized to deliver survivorship care at scale and struggles to support the increasing number of survivors across the cancer care continuum. Increasing patient loads in specialty clinics result in brief and infrequent follow-up visits, leaving patients without the opportunity to ask questions and fully understand their health status, all the while tasking providers with making quick and effective treatment decisions with minimal patient information or interaction.

In order to address this increasing need for improved care delivery, investigators have developed the Ned ("No Evidence of Disease") PCa survivorship platform, which allows patients to access clinical information (i.e. lab results), virtually complete patient reported outcomes (PROs) on their quality of life, and complete virtual visits with their specialist. Despite the promise and potential of Ned, ongoing evaluation of this platform shows specialists often lacked the availability and flexibility to consistently review ePROs and lab results prior to a study visit. In response, researchers aim to expand the current Ned platform to design, develop and implement a digitally mediated nurse-led survivorship care model that can address the growing needs of prostate cancer survivors and healthcare providers at scale.

In this trial, investigators aim to evaluate the effectiveness of a nurse-led survivorship care model by comparing the clinical outcomes of patients enrolled in the Specialist Ned Clinic (control) for their PCa follow-up care and those that will be enrolled into the Nurse Ned Clinic (intervention) a year later. Participants will be enrolled in the study for one year, and will be asked to complete standardized questionnaires related to their PCa follow-up care at the start of the study, 6-months into using their respective Ned Clinic and at study completion.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer